Inventiva(US:IVA)2026-03-02 16:32Summary of Inventiva FY Conference Call (March 02, 2026) Company Overview - Company: Inventiva (NasdaqGM: IVA) - Focus: Ongoing phase three NATiV3 trial for NASH (Non-Alcoholic Steatohepatitis) treatment Key Points Industry and Product Insights - NASH Market: The NASH market is competitive, with existing players showing modest effect sizes. Inventiva aims to demonstrate a significant improvement in fibrosis and NASH resolution through its drug, lanifibranor [1][2] - Phase Three NATiV3 Trial: The trial is designed similarly to the previous NATIVE two trial, focusing on a combined primary endpoint of fibrosis and NASH resolution. The trial excludes F1 patients, potentially providing a competitive advantage [6][9] - Expected Outcomes: A target of approximately 20% effect on fibrosis is anticipated, which could significantly disrupt the current market by doubling existing effect sizes [9][10] Clinical Data and Safety - Previous Trials: The NATIVE two trial showed a 24% dual endpoint resolution and 18% fibrosis improvement at six months, setting a benchmark for NATiV3 [6][10] - Safety Concerns: Previous safety issues related to hepatic events have been addressed, with ongoing monitoring and assessments showing no significant concerns in the current trial [16][21] - Weight Gain and Tolerability: In phase IIb, 50% of patients showed no weight gain, while one-third experienced over 5% weight gain. The company emphasizes that treatment efficacy is not dependent on weight gain [26][37] Market Strategy and Commercialization - Pre-commercialization Efforts: A chief commercial strategy officer has been appointed to enhance market access and engage with key opinion leaders (KOLs) [73][80] - Target Population: The diabetic NASH population is identified as a significant opportunity, with about 70% of NASH patients also having diabetes. The company plans to focus on the full spectrum of F2 and F3 patients, including those with type 2 diabetes [210][217] Future Trials and Regulatory Considerations - F4 MASH Confirmatory Trial: Plans for a confirmatory trial in F4 MASH are in place, with the requirement to run an outcome study for full approval. The trial is expected to start around the time of the NDA filing in 2027 [94][104] - Patient Selection: The strategy involves enrolling patients with significant portal hypertension to ensure a higher event rate, which is crucial for powering the trial [135][144] Financial Position - Cash Position: As of the end of 2025, the company has EUR 231 million in cash, projected to last through Q3 2027, assuming positive trial data. A EUR 149 million raise was completed in November 2025 [195][196] Combination Therapies - Potential for Combination: Lanifibranor's unique mechanism allows for potential combination therapies, particularly with GLP-1s for diabetes management and cardiovascular risk reduction [197][205] Additional Insights - Market Dynamics: The company acknowledges the evolving landscape of combination therapies in the NASH space and is open to exploring these opportunities as data becomes available [197][205] - Investor Communication: The company aims to provide clear guidance on trial data and market strategies as they progress through the year [39][56] This summary encapsulates the key discussions and insights from the Inventiva FY Conference Call, highlighting the company's strategic direction, clinical trial progress, and market positioning in the NASH treatment landscape.